+91-8668442535
Home / Biotechnology / Cervical D

Cervical Dysplasia Diagnostic Market By Type (Diagnostic Test, Diagnostic Device) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Cervical carcinoma accounts for around 15% of all cancers diagnosed in women. Every year, approximately 5 lakh new cases of cervical cancer in women are reported, with developing countries accounting for 80% of these cases. Cervical dysplasia is a major health problem among women, especially in developing countries with a rising incidence of cancer. It is detected in women in their 20s, and the peak incidence ranges between 25 and 35 years, while the incidence of cervical cancer rises after 40 years. With rising awareness about cervical dysplasia, improvements in screening technology have led to early diagnosis and treatment to further avoid the progression of the disease. WHO and the national government are making efforts to build national cancer strategies based on the local need for early treatment and prevention of disease, which would help in the growth of the cervical dysplasia diagnostic market.

The report titled "Cervical Dysplasia Diagnostic Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall cervical dysplasia diagnostic market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on diagnosis type and different geographies.

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. This section also includes additional cross-sectional analysis presented in terms of diagnosis type and constituent region/country level markets.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global cervical dysplasia diagnostic market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global cervical dysplasia diagnostic market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global cervical dysplasia diagnostic market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the cervical dysplasia diagnostic market. The key players profiled in this report are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Helix BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic Technologies Ltd., OncoHealth Corporation, PDS Biotechnology Corporation, Photocure ASA, Quest Diagnostics, Inc., QIAGEN N.V., and others.

Based on the type of diagnosis, the global cervical dysplasia diagnostic market is segmented as follows:

Diagnostic Test

  • HPV Test
  • Pap smear examination
  • Biopsy

Diagnostic Device

  • Colposcopy

Diagnostic tests occupy the largest share, thus dominating the cervical dysplasia diagnostic market. With advancements in diagnostic technology and increased awareness about cervical dysplasia, there is a rise in screening programs for early diagnosis and treatment of the disease, which contribute to the growth of the diagnostic test segment of the cervical dysplasia diagnostic market. The Pap smear test is the most common, simple, and painless test used for detecting cervical dysplasia. However, due to errors in the results in almost 15–25% of cases, other tests, such as HPV, are being aggressively used. The HPV testing market is anticipated to grow fast in the forecast period due to advancements in technology and the preference for Pap smear tests due to false-negative results. Diagnostic devices such as colposcopies are used if the cervical cells are distinctly abnormal.

For the purpose of this study, the global cervical dysplasia diagnostic market is geographically categorized into:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

In 2016, North America dominated the global cervical dysplasia diagnostic market, followed by Europe. Annually, around 250,000 to 1 million women in the U.S. are diagnosed with cervical dysplasia. Some of the major causes of cervical dysplasia are the rising prevalence of various sexually transmitted diseases (STDs) and the adoption of unhealthy lifestyles such as drinking, smoking, and drug use. There is an increase in awareness about the occurrence and progress of cervical dysplasia, a rise in government funds for screening programs, continuously evolving diagnostic technology, and favorable reimbursement policies, which are some of the key factors contributing to the growth of the cervical dysplasia diagnostic market. Asia Pacific is anticipated to be the fastest-growing regional market in the forecast period of 2017–2025.

The rise in the prevalence of cervical cancer, increasing investment in the development of healthcare, awareness about cervical cancer, and novel diagnostic and treatment options are the key driving factors for cervical dysplasia. With the increase in mortality associated with cervical cancer, government-funded screening programs are being initiated for early diagnosis and treatment to improve the quality of life in developing countries. Emerging economies such as China and India are expected to be lucrative markets in the forecast period.

Frequently Asked Questions:

The market for Cervical Dysplasia Diagnostic Market is expected to reach US$ 791.3 Mn By 2025.

The Cervical Dysplasia Diagnostic Market is expected to see significant CAGR growth over the coming years, at 6.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Helix BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic Technologies Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Biotechnology
Report ID:   58678
Report Format:   PDF
Pages:   120
Rating:    4.7 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support